Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

21.97
-0.4100-1.83%
Volume:70.78K
Turnover:1.57M
Market Cap:2.73B
PE:-173.18
High:22.53
Open:22.23
Low:21.88
Close:22.38
52wk High:31.77
52wk Low:11.86
Shares:124.03M
Float Shares:88.24M
Volume Ratio:0.44
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1269
EPS(LYR):-0.1269
ROE:-9.30%
ROA:-1.95%
PB:14.38
PE(LYR):-173.18

Loading ...

Assessing Arcutis Biotherapeutics After 99% Rally and DCF Signals Further Upside Potential

Simply Wall St.
·
Dec 13, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Simply Wall St.
·
Dec 09, 2025

Arcutis Biotherapeutics Files Initial Beneficial Ownership Statement for Director Amit Munshi

Reuters
·
Dec 09, 2025

Amit Munshi Joins Arcutis Board as Bhaskar Chaudhuri Retires

Reuters
·
Dec 09, 2025

Press Release: Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

Dow Jones
·
Dec 09, 2025

Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
Dec 04, 2025

U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams

Reuters
·
Nov 28, 2025

Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $37 From $32

THOMSON REUTERS
·
Nov 28, 2025

Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
Nov 27, 2025

Arcutis Biotherapeutics (ARQT) Is Up 17.5% After FDA Review Accepted for Pediatric ZORYVE Expansion - Has The Bull Case Changed?

Simply Wall St.
·
Nov 25, 2025

Arcutis Biotherapeutics CEO Todd Watanabe Reports Disposal of Common Shares

Reuters
·
Nov 25, 2025

Director Halley E. Gilbert Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
Nov 22, 2025

Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older

Reuters
·
Nov 20, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20, 2025

FDA Accepts Arcutis Supplemental Application for ZORYVE Cream in Young Children with Plaque Psoriasis

Reuters
·
Nov 17, 2025

Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Date for June 29, 2026

THOMSON REUTERS
·
Nov 17, 2025

FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (Roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

THOMSON REUTERS
·
Nov 17, 2025

Executive VP & Chief Commercial Officer Of Arcutis Biotherapeutics Sold 40% Of Their Shares

Simply Wall St.
·
Nov 14, 2025

Arcutis Biotherapeutics Completes Enrollment for Phase 2 Study of Investigational Treatment for Atopic Dermatitis

MT Newswires Live
·
Nov 13, 2025

BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older

Reuters
·
Nov 13, 2025